A precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumors: An open-label, prospective, multicenter clinical study (PRaG 5.0 study).

Who was studied?

6 evaluable patients with advanced solid tumors after systemic treatment.

What does the publication report?

ORR was 33.3% and DCR 50.0%. Exploratory single-cell analysis described changes in T-cell states.

Safety findings

The abstract calls toxicity manageable but does not provide a complete graded adverse-event table.

How should we interpret it?

Conference-level, non-randomized evidence. Linked reports may include the same participants and should not be counted as independent trials.

Read the original source

This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.

A precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumors: An open-label, prospective, multicenter clinical study (PRaG 5.0 study). · DOI: 10.1200/JCO.2024.42.16_suppl.e14637

• Official publication source ↗
• Publisher via DOI ↗

Related publications from the same research program

• PRaG 5.0: Personalized thymosin alpha-1 and radioimmunotherapy for advanced refractory solid tumors—Data from an expanded cohort.
• Thymosin alpha-1–enhanced PRaG regimen: A novel approach to boosting immune dynamics and therapeutic efficacy in advanced solid tumors.
• Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre study (PRaG5.0 study)

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.